Long-term metastatic melanoma survival dramatically improves on immunotherapy: Study

Long-term data from a landmark international trial show that about half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors live cancer-free for 10 years or more, according to a new report from Weill Cornell Medicine and Dana-Farber Cancer Centre investigators and colleagues.